X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (37) 37
male (29) 29
female (26) 26
middle aged (26) 26
adult (22) 22
hematology (22) 22
adolescent (17) 17
aged (16) 16
oncology (16) 16
antineoplastic combined chemotherapy protocols - therapeutic use (15) 15
remission induction (11) 11
treatment outcome (11) 11
index medicus (9) 9
aged, 80 and over (8) 8
prognosis (8) 8
cytarabine - administration & dosage (7) 7
imatinib mesylate (7) 7
survival analysis (7) 7
therapy (7) 7
benzamides (6) 6
child (6) 6
cml (6) 6
disease-free survival (6) 6
france (6) 6
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (6) 6
pyrimidines - administration & dosage (6) 6
child, preschool (5) 5
dasatinib (5) 5
hematopoietic stem cell transplantation (5) 5
life sciences (5) 5
minimal residual disease (5) 5
piperazines - administration & dosage (5) 5
pyrimidines - adverse effects (5) 5
retrospective studies (5) 5
time factors (5) 5
translocation, genetic (5) 5
antineoplastic agents - adverse effects (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
bone-marrow-transplantation (4) 4
chronic myeloid leukemia (4) 4
chronic myeloid-leukemia (4) 4
combined modality therapy (4) 4
drug administration schedule (4) 4
fusion proteins, bcr-abl - genetics (4) 4
high-dose cytarabine (4) 4
immunohistochemistry (4) 4
interferon (4) 4
leukemia, myelogenous, chronic, bcr-abl positive - genetics (4) 4
leukemia, myelogenous, chronic, bcr-abl positive - pathology (4) 4
pathology (4) 4
philadelphia chromosome (4) 4
piperazines - adverse effects (4) 4
precursor cell lymphoblastic leukemia-lymphoma - mortality (4) 4
recurrence (4) 4
risk factors (4) 4
abridged index medicus (3) 3
acute myelogenous leukemia (3) 3
acute myeloid-leukemia (3) 3
antileukemic agents (3) 3
antineoplastic agents - administration & dosage (3) 3
bcr-abl (3) 3
bcr-abl mutations (3) 3
cells (3) 3
chemotherapy (3) 3
chronic myelogenous leukemia (3) 3
clinical trial (3) 3
cytarabine (3) 3
cytarabine - therapeutic use (3) 3
daunorubicin - administration & dosage (3) 3
fish (3) 3
follow-up (3) 3
follow-up studies (3) 3
fusion proteins, bcr-abl - analysis (3) 3
gene (3) 3
herpesvirus 4, human - isolation & purification (3) 3
hodgkin disease - pathology (3) 3
hodgkin disease - virology (3) 3
idarubicin - administration & dosage (3) 3
imatinib (3) 3
imatinib resistance (3) 3
in situ hybridization (3) 3
infant (3) 3
intensive chemotherapy (3) 3
interferon-alpha (3) 3
interferon-alpha - administration & dosage (3) 3
interferon-alpha - adverse effects (3) 3
leukemia (3) 3
leukemia, myeloid, acute - drug therapy (3) 3
leukemia, myeloid, chronic-phase - drug therapy (3) 3
leukemia, promyelocytic, acute - drug therapy (3) 3
lymphoma, b-cell - genetics (3) 3
lymphoma, non-hodgkin - pathology (3) 3
management (3) 3
multicenter studies as topic (3) 3
neoplasms (3) 3
nilotinib (3) 3
patient selection (3) 3
peg-interferon (3) 3
piperazines - therapeutic use (3) 3
polyethylene glycols - administration & dosage (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer, ISSN 0008-543X, 07/2018, Volume 124, Issue 14, pp. 2956 - 2963
BACKGROUND The ultimate goal of chronic myeloid leukemia management in the tyrosine kinase inhibitor (TKI) era for patients who obtain deep molecular responses... 
tyrosine kinase inhibitors | chronic myeloid leukemia | clinical practice | treatment discontinuation | recommendations | TREATMENT-FREE REMISSION | MANAGEMENT | IMATINIB CESSATION | DASATINIB | NILOTINIB | RELAPSE | IMPACT | ONCOLOGY | DISEASE | DEEP MOLECULAR RESPONSE | CML PATIENTS | Prognosis | Age Factors | Fusion Proteins, bcr-abl - isolation & purification | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Patient Selection | Young Adult | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Fusion Proteins, bcr-abl - blood | Adult | Remission Induction - methods | France | Neoplasm Recurrence, Local - blood | Watchful Waiting - standards | Patient Education as Topic | Medical Oncology - methods | Neoplasm Recurrence, Local - prevention & control | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - blood | Hematology - standards | Treatment Outcome | Neoplasm Recurrence, Local - diagnosis | Consensus | Hematology - methods | Protein Kinase Inhibitors - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Medical Oncology - standards | Fusion Proteins, bcr-abl - metabolism | Tyrosine | Medical personnel | Myeloid leukemia | Physicians | Leukemia | Medical services | Chronic myeloid leukemia | Patients | Reintroduction | Biologists | Molecular chains | Training | Remission | Clinical medicine | Protein-tyrosine kinase | Monitoring | Cancer | Life Sciences | Hematology | Human health and pathology
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2010, Volume 363, Issue 26, pp. 2511 - 2521
In this study, adding pegylated interferon alfa-2a to imatinib therapy for chronic myeloid leukemia resulted in a greater reduction in the number of cells... 
CHRONIC MYELOGENOUS LEUKEMIA | CHROMOSOME | MEDICINE, GENERAL & INTERNAL | INTERFERON | CML | ABL TYROSINE KINASE | HEMATOPOIETIC STEM-CELLS | FOLLOW-UP | PATIENTS RECEIVING IMATINIB | QUIESCENT | CYTARABINE | Piperazines - administration & dosage | Humans | Leukemia, Myeloid, Chronic-Phase - pathology | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Polyethylene Glycols - adverse effects | Male | Proto-Oncogene Proteins c-abl - analysis | Cytarabine - adverse effects | Recombinant Proteins | RNA, Neoplasm - analysis | Adult | Female | Transcription, Genetic | Neutropenia - chemically induced | Proto-Oncogene Proteins c-abl - genetics | Pyrimidines - administration & dosage | Leukemia, Myeloid, Chronic-Phase - drug therapy | Anemia - chemically induced | Treatment Outcome | Thrombocytopenia - chemically induced | Imatinib Mesylate | Piperazines - adverse effects | Remission Induction | Cytarabine - administration & dosage | Polyethylene Glycols - administration & dosage | Interferon-alpha - administration & dosage | Leukemia, Myeloid, Chronic-Phase - mortality | Fusion Proteins, bcr-abl - genetics | Fusion Proteins, bcr-abl - analysis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - adverse effects | Survival Analysis | Stem Cells - drug effects | Interferon-alpha - adverse effects | Benzamides | Drug therapy | Chronic myeloid leukemia | Medical research | Kinases | Leukemia | Manuscripts
Journal Article
Journal Article
Blood, ISSN 0006-4971, 02/2007, Volume 109, Issue 4, pp. 1408 - 1413
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2009, Volume 27, Issue 16, pp. 2668 - 2676
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2017, Volume 35, Issue 3, pp. 298 - 305
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 11/2019, Volume 25, Issue 22, pp. 6606 - 6613
Purpose: Tyrosine kinase inhibitor (TKI) discontinuation is an emerging goal in chronic myelogenous leukemia (CML) management and several studies have... 
RELAPSE | ONCOLOGY | DISCONTINUATION | CHRONIC MYELOID-LEUKEMIA | REMISSION | Life Sciences | Hematology | Human health and pathology
Journal Article
Blood, ISSN 0006-4971, 10/2002, Volume 100, Issue 7, pp. 2357 - 2366
Journal Article
Journal Article
Blood, ISSN 0006-4971, 12/2003, Volume 102, Issue 13, pp. 4298 - 4305
Journal Article
Blood, ISSN 0006-4971, 07/2003, Volume 102, Issue 2, pp. 462 - 469
Journal Article
Blood, ISSN 0006-4971, 05/2002, Volume 99, Issue 10, pp. 3517 - 3523
Journal Article
Clinical cancer research : an official journal of the American Association for Cancer Research, ISSN 1078-0432, 07/2019
TKI discontinuation is an emerging goal in CML management and several studies demonstrated the feasibility of stopping safely imatinib. A sustained DMR on... 
Journal Article